Vaderis Therapeutics raises USD 152 M

Vaderis Therapeutics develops targeted therapies for rare vascular diseases, including engasertib for hereditary haemorrhagic telangiectasia. The Basel biotech raised USD 152 million in a Series B co-led by Goldman Sachs Alternatives and TCGX, to fund its phase 3 study through to a possible US approval.

Announced on
Round
Series B
Amount
USD 152 M
Location
Basel, canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic